Drugs / Ad26.HPV16
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03610581 | Sep 2018 → Oct 2020 | human papilloma virus infection | Janssen Vaccines & Prevention B.V. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad26.HPV16 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03610581 ↗ |
| Modality | Vaccine | “Ad26- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components” NCT03610581 ↗ |
| Route | Intramuscular | “Participants will receive Ad26.HPV16 as a solution for intramuscular injection.” NCT03610581 ↗ |